TB-500 and thymosin beta-4: the name matters

A full peptide and a fragment

Thymosin beta-4 is a peptide containing 43 amino acids. In FDA's 2026 TB-500 assessment, TB-500 refers to an acetylated seven-amino-acid fragment associated with positions 17 through 23 of that longer sequence. They are related, but they are different substances. FDA specifically notes that some websites use their names interchangeably.

For a reader, this creates a practical problem. A headline may say TB-500 while the cited experiment actually used full-length thymosin beta-4 or a different fragment. Before judging the result, check the methods for the sequence, chemical modifications and formulation. A familiar abbreviation is not enough to establish that two studies tested the same material.

Where the repair interest comes from

In a 2003 study, Philp and colleagues examined skin-wound repair in animal models, including aged and diabetic mice. They reported effects of thymosin beta-4 on several repair measurements. A shorter synthetic sequence, LKKTETQ, also showed activity in the aged-animal model. This work helped frame questions about which parts of the longer peptide contribute to particular biological effects.

The FDA briefing explains a further distinction: results for a non-acetylated fragment cannot be directly transferred to an acetylated one. Chemical modification may change a molecule's properties. Similar sequences and a shared research history do not eliminate the need to test each material.

Human research must stay attached to its context

Human studies of thymosin beta-4 formulations do exist. For example, a small randomized study published in 2015 investigated an ophthalmic formulation in nine people with severe dry eye. It reported improvements in certain eye signs and symptoms compared with the control. Its subject was an eye formulation and a particular condition, not systemic recovery or a sports injury.

That distinction holds even when a result is encouraging. An eye study cannot establish that a different peptide fragment improves tendon recovery. Nor does a trial of a specified formulation establish the quality, safety or effectiveness of a separate retail product.

Read the uncertainty alongside the findings

FDA's briefing for the July 2026 committee meeting reported that its review had not identified clinical studies of TB-500 administered to humans and could not establish its effectiveness for wound healing. It also described substantial safety-information gaps. This is a dated evidence assessment, not a claim that future research cannot change the picture.

When reviewing a new paper, record the exact substance, model, outcome and follow-up period. That small habit prevents a whole family of related molecules from being credited with a benefit demonstrated for only one of them.

Sources & further reading

• FDA (2026): TB-500 identity, evidence and safety briefing
• Philp et al. (2003): thymosin beta-4 and fragment in animal wound models
• Sosne et al. (2015): small randomized thymosin beta-4 ophthalmic study